+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07507760

Evaluating Oral Decitabine Plus Ivosidenib in Adults with Newly Diagnosed Acute Myeloid Leukemia Who Are Older or Unfit for Standard Chemotherapy

Led by PETHEMA Foundation · Updated on 2026-09-22

50

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of oral decitabine and ivosidenib as a first-line treatment for adults with newly diagnosed acute myeloid leukemia AML who have an IDH1 R132 mutation. This study focuses on older adults aged 60 years and above, or adults aged 18 years and older with specific health conditions that make them unsuitable for standard intensive chemotherapy. The main goals are to assess the rates of complete remission and incomplete marrow recovery, as well as to monitor the occurrence and severity of any adverse events. Participants will receive treatment cycles lasting 28 days, consisting of oral ivosidenib taken daily for 28 days and oral decitabine-cedazuridine tablets taken once daily for the first 5 days of each cycle. During screening and the first two treatment cycles, hydroxyurea or cytarabine may be used to control high white blood cell counts. Those who achieve remission may be eligible for allogeneic stem cell transplantation, after which they can resume ivosidenib treatment from day 60 post-transplant, continuing for up to two years. Throughout the study, participants will have regular assessments to monitor their response to treatment, including disease progression and any side effects. Those undergoing transplant will have additional evaluations before and after the procedure, including minimal residual disease statistics. The researchers will measure remission rates over three years, along with overall survival, event-free survival, quality of remission, and early mortality. Participants are followed until disease progression, unacceptable toxicity, withdrawal, or study completion, expected by April 2029.

CONDITIONS

Brief Title

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Research Team

P

Pau Montesinos

J

Juan José Lahuerta

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here